Skip to content

What are the current clinical trial regulations in Finland?

← All articles

In Finland, the rules for a study depend on what you are testing. A medicine trial is authorised under the EU Clinical Trials Regulation (CTR, Regulation (EU) No 536/2014). The sponsor applies through CTIS, Fimea (the Finnish Medicines Agency) is the authority, and Tukija (the National Committee on Medical Research Ethics) gives the ethics opinion. A medical device or IVD study follows the MDR or IVDR together with Finnish law. For a stand-alone device or IVD study, a regional ethics committee gives its opinion first, and only then does the sponsor apply to Fimea. A study that combines a medicine with a device or an IVD has to meet both sets of rules, and Tukija does the ethics review.

Which route applies to your study?

Study type Ethics review Authority How you submit Order of review
Medicine trial under the CTR Tukija Fimea CTIS Side by side
Medicine trial sent only to Finland Tukija Fimea CTIS, accelerated national schedule in use since 11 February 2026 Side by side; decision can come within 30 calendar days if no questions arise
Device clinical investigation (MDR) Regional medical research ethics committee Fimea Application or notification to Fimea Ethics opinion first
IVD performance study (IVDR) Regional medical research ethics committee Fimea Application or notification to Fimea Ethics opinion first
Medicine trial combined with a device or IVD Tukija, for the whole study Fimea, for both the medicine part and the device or IVD part CTIS for the medicine, Fimea for the device or IVD Medicine part usually assessed first; the ethics-first rule for the device part can be set aside; no harmonised process yet

Who reviews a medicine trial in Finland?

Fimea is the authority, and Tukija, a single national committee, gives the ethics opinion on clinical drug trials in Finland. Under the Finnish Act on Clinical Trials on Medicinal Products, regional ethics committees have no assessment role in drug trials. Fimea and Tukija both take part in the assessment. They alone assess the Finnish part of the application (Part II), while Part I is assessed together with the other EU and EEA countries you include.

How does the EU Clinical Trials Regulation apply in Finland?

The CTR and the Finnish Act on Clinical Trials on Medicinal Products (983/2021) have applied since 31 January 2022. The transition period for trials started under the old rules ended on 31 January 2025. Medicine trials are now submitted through CTIS, the EU’s Clinical Trials Information System.

The application has two parts. Part I covers the protocol and the investigational product and goes to all the EU or EEA countries you choose at the same time. Part II covers national matters such as the material given to participants, the investigators and sites, and insurance, and is assessed only by the authorities of the country concerned. You can file Part II together with Part I or later, once Part I has been processed. If Part II is not filed within two years, the trial lapses.

The Regulation leaves some matters to the Member States. In Finland the Act covers, for example, investigator qualifications, the language of the application documents, fees, and the processing of personal data.

What is the 30-day route for trials sent only to Finland?

On 11 February 2026 Fimea and Tukija introduced an accelerated schedule for national applications, that is, trial applications sent only to Finland. It applies to all of them, whatever the phase of the trial or the sponsor. Applications that also go to other countries follow the normal CTIS schedule.

Day 0 is the day the application reaches CTIS, and questions in the validation phase do not stop the clock. An application sent on a Friday, at a weekend or on a midweek public holiday counts as received on the next working day, which is why Fimea advises against submitting on a Friday.

If no requests for more information or corrections are needed in the evaluation phase, a decision can come within 30 calendar days of submission. If there are questions, the sponsor has 12 days to answer and the authorities then have 10 days to assess the answers, and the decision date moves accordingly.

What do device and IVD studies need?

The CTR does not cover devices or IVDs. Clinical investigations of devices fall under the MDR (Regulation (EU) 2017/745) and performance studies of IVDs under the IVDR (Regulation (EU) 2017/746). The Finnish Medical Devices Act (719/2021) adds the national rules.

For a stand-alone device or IVD study, the ethics opinion comes from a regional medical research ethics committee: the one for the area where the study will mainly take place. If there is no main area, the sponsor chooses one of the regional committees where the study runs. The sponsor can submit the application to Fimea only once the committee has given its opinion, and Fimea’s IVD page says the opinion is also needed before a notification. So for these studies the ethics and authority reviews run one after the other, whereas for drug trials they run side by side.

Whether Fimea needs an application or a notification depends on the device, its CE mark and the purpose of the study. For devices, Fimea describes applications under Article 62 or Article 82 of the MDR and notifications under Article 74(1). For IVD performance studies, Fimea lists the cases that need an application, for example when a sample is taken by a surgically invasive procedure only for the study. Studies that use only left-over samples are notified to Fimea at least 10 days before they start. Our page on medical device and IVD studies in Finland walks through the routes.

What about studies that combine a medicine with a device or IVD?

Here both sets of rules apply. The medicine part is a CTR trial and goes through CTIS, while the device or IVD part falls under the MDR or IVDR and is assessed by the device authority, which in Finland is also Fimea.

Ethics review works differently from a stand-alone device study: when a device or IVD study is combined with a drug trial, the ethics review is done by Tukija rather than a regional committee. The Medical Devices Act also lets the usual rule, that the device application waits for the ethics opinion, be set aside when the assessment of the drug trial requires it. Tukija asks for the device documents to be submitted at the same time as the medicine trial application, and for documents with identical content not to be submitted twice.

According to Fimea, the drug trial is in most cases assessed first, and the study then goes to the device authority. Finland has no harmonised process for this yet, so plan both routes together from the start.

At EU level, the European Commission, the participating Member States and the EMA are piloting a coordinated assessment of combined studies called COMBINE. Phase 2 of the pilot was launched on 26 June 2026. It is open to a medicine trial combined with a device clinical investigation or an IVD performance study, and the Commission’s sponsor guide sets out the eligibility criteria. The Commission’s page does not list the participating countries, so check the sponsor guide before you plan on it.

Which language must the documents be in?

  • Medicine trials, application documents. The documents listed in Annexes I and II of the CTR, such as the protocol and the investigator’s brochure, may be in Finnish, Swedish or English.
  • Medicine trials, recruitment and consent documents. These have to be in Finnish or Swedish: the recruitment material in Annex I, point 60 (advertising material, invitations to take part, and the procedure for handling responses), and the documents in Annex I, part L (the information given to participants, the informed consent form and the description of the consent procedure).
  • Finnish or Swedish. The Act says “Finnish or Swedish”. On its own it does not require both versions for every trial, so agree early with Tukija and your sites which language versions the study will use, especially if sites are in bilingual areas or will recruit Swedish-speaking participants.
  • Device and IVD studies. Application documents may be in Finnish, Swedish or English. Under the Medical Devices Act, the summary of the investigation plan and the participant information and consent documents have to be in Finnish or Swedish. For device investigations this includes the description of the informed consent process. Fimea’s IVD page states the same rule for IVD studies: the plan itself may be in English, but its summary, the subject information sheet and the consent form must be in Finnish or Swedish.
  • Labels of investigational medicines. Finnish and, where needed, Swedish. Labels can be in English instead when the medicine is given by trial staff rather than by the participant.

What national requirements apply on top of the EU rules?

Insurance is the main one. The sponsor has to make sure that insurance or another suitable security is in force to cover harm to participants and the liability of the sponsor and the investigator. This comes from the Finnish Act on Clinical Trials on Medicinal Products, and the CTR in turn requires each Member State to have compensation systems in place in the form of insurance, a guarantee or a similar arrangement. The insurance details are part of Part II. The Medical Devices Act has a matching requirement for device and IVD studies.

Apart from insurance and the language rules above, the Finnish Act sets national rules on investigator qualifications, on participants with reduced capacity to consent, minors, and prisoners or forensic psychiatric patients, and on fees. Personal data in trials is processed under the General Data Protection Regulation (EU) 2016/679, and the Act has its own section on the processing of personal data in clinical drug trials.

How are participant rights and informed consent handled?

The CTR sets the rules in Chapter V, “Protection of subjects and informed consent” (Articles 28 to 35). Informed consent is the participant’s free and voluntary decision to take part after being told everything relevant to that decision. It has to be written, dated and signed. Chapter V has additional rules for cluster trials, incapacitated subjects, minors, pregnant or breastfeeding women and emergency situations, and lets Member States keep some additional national measures. Tukija assesses the consent and recruitment materials as part of the Finnish review.

Tukija publishes a template for the information and consent document. On 3 June 2026 it published updated guidance on the description of consent procedures and recruitment for drug trials, and on 26 June 2026 it made small updates to the information and consent template. Check that you are working from the current versions when you prepare the Finnish and Swedish documents.

How RecQ can help

RecQ prepares ethics committee and Fimea submissions, CTIS applications and site documents for medicinal product, device and IVD studies. Our own team negotiates research permits and site agreements with hospitals, in Finland and the other Nordic countries. Finnish- and Swedish-speaking CRAs write and check the participant documents that have to be in the national languages, and we translate trial documents into every Nordic language. Monitoring and archiving come under the same master service agreement, which covers every RecQ service. You pay for the hours actually worked, and one person at RecQ stays your contact for the whole study.

See our services overview or the page on medical device and IVD studies in Finland.

Request a proposal

Sources (checked 22 October 2026)

Need a CRA in Finland? RecQ’s core CRA team monitors clinical trials in Finland and across the Nordic countries: Hiring a CRA in Finland. A CRA yourself? For consultants.